16-Dehydropregnenolone acetate is an impurity of Abiraterone, which is a CYP17A1 inhibitor and by extension androgen synthesis inhibitor. In combination with prednisone, it is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have already received prior chemotherapy containing docetaxel under the trade name Zytiga. Source summary: 16-Dehydropregnenolone acetate: research-use steroid acetate for biochemical studies and chemical synthesis; catalog compound for lab reference.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Endocrinology and Metabolic Disease | 5 alpha Reductase
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.